Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia

[11C](R)PK11195-PET measures upregulation of translocator protein, which is associated with microglial activation, [11C]PIB-PET is a marker of amyloid, while [18F]FDG-PET measures cerebral glucose metabolism (rCMRGlc). We hypothesize that microglial activation is an early event in the Parkinson’s disease (PD) spectrum and is independent of the amyloid pathology. The aim of this study is to evaluate in vivo the relationship between microglial activation, amyloid deposition, and glucose metabolism in Parkinson’s disease dementia (PDD) and PD subjects without dementia. Here, we evaluated 11 PDD subjects, 8 PD subjects without dementia, and 24 control subjects. Subjects underwent T1 and T2 MRI, [11C](R)PK11195, [18F]FDG, and [11C]PIB PET scans. Parametric maps of [11C](R)PK11195 binding potential, rCMRGlc, and [11C]PIB uptake were interrogated using region of interest and SPM (statistical parametric mapping) analysis. The PDD patients showed a significant increase of microglial activation in anterior and posterior cingulate, striatum, frontal, temporal, parietal, and occipital cortical regions compared with the controls. The PD subjects also showed a statistically significant increase in microglial activation in temporal, parietal, and occipital regions. [11C]PIB uptake was marginally increased in PDD and PD. There was a significant reduction in glucose metabolism in PDD and PD. We have also demonstrated pixel-by-pixel correlation between mini-mental state examination (MMSE) score and microglial activation, and MMSE score and rCMRGlc. In conclusion, we have demonstrated that cortical microglial activation and reduced glucose metabolism can be detected early on in this disease spectrum. Significant microglial activation may be a factor in driving the disease process in PDD. Given this, agents that affect microglial activation could have an influence on disease progression.

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  T. Spinks,et al.  Physical characteristics of the ECAT EXACT3D positron tomograph. , 2000, Physics in medicine and biology.

[3]  William E. Klunk,et al.  The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component , 2003, The Journal of Neuroscience.

[4]  T. Jones,et al.  Spectral Analysis of Dynamic PET Studies , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Comparison of cerebral glucose metabolism between multiple system atrophy Parkinsonian type and Parkinson's disease , 2008, Neurological research.

[6]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[7]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Joon-Kee Yoon,et al.  A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies , 2007, European journal of neurology.

[9]  Y. Itoyama,et al.  Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment , 2009, Movement disorders : official journal of the Movement Disorder Society.

[10]  P. Mcgeer,et al.  Cortical glucose metabolism in parkinson's and alzheimer's disease , 1990, Journal of neuroscience research.

[11]  Alexander Hammers,et al.  In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.

[12]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[13]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[14]  K. Jellinger,et al.  Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? , 2006, Acta Neuropathologica.

[15]  Albert Gjedde,et al.  Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages , 2010, Brain Structure and Function.

[16]  F. Turkheimer,et al.  Reference and target region modeling of [11C]-(R)-PK11195 brain studies. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  R B Banati,et al.  The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.

[18]  Mark E. Schmidt,et al.  The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[19]  S. Hume,et al.  Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. , 1994, Nuclear medicine and biology.

[20]  C. Becker,et al.  Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics , 2009, Neurobiology of Disease.

[21]  Albert Gjedde,et al.  Subcortical elevation of metabolism in Parkinson's disease — A critical reappraisal in the context of global mean normalization , 2009, NeuroImage.

[22]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[23]  B. Långström,et al.  The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.

[24]  R. Albin,et al.  Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  M Samii,et al.  Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [18F]FDG‐PET , 2001, Movement disorders : official journal of the Movement Disorder Society.

[26]  Matthias Reimold,et al.  [11C]PIB binding in Parkinson's disease dementia , 2008, NeuroImage.

[27]  W. Klunk.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia , 2011, Neurobiology of Aging.

[28]  Alexander Hammers,et al.  Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.

[29]  J. Cummings,et al.  Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates , 1988, Journal of geriatric psychiatry and neurology.

[30]  V J Cunningham,et al.  Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. , 2000, Brain : a journal of neurology.

[31]  P. Mcgeer,et al.  Inflammation and the Degenerative Diseases of Aging , 2004, Annals of the New York Academy of Sciences.

[32]  G Brix,et al.  Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  이필휴.  A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies , 2007 .

[34]  Andre Parent,et al.  Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.

[35]  Belinda Wilson,et al.  Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[37]  M Schulzer,et al.  Cerebral glucose metabolism in Parkinson's disease with and without dementia. , 1992, Archives of neurology.

[38]  H. Ross,et al.  A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease , 2000, Neurology.

[39]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[40]  Masayuki Sasaki,et al.  Regional cerebral glucose metabolism in patients with Parkinson’s disease with or without dementia , 1992, Annals of nuclear medicine.

[41]  T D Cradduck,et al.  National electrical manufacturers association , 1983, Journal of the A.I.E.E..

[42]  Keith A. Johnson,et al.  Imaging amyloid deposition in Lewy body diseases , 2008, Neurology.

[43]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[44]  Johannes C. Klein,et al.  Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo , 2010, Neurology.

[45]  William J. Jagust,et al.  Cortical glucose metabolism in Parkinson's disease without dementia , 1994, Neurobiology of Aging.

[46]  Alexander Hammers,et al.  A systematic comparison of kinetic modelling methods generating parametric maps for [11C]-(R)-PK11195 , 2007, NeuroImage.

[47]  Martin Rossor,et al.  Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study , 2008, Neurobiology of Disease.

[48]  D. Perani,et al.  In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. , 2013, Parkinsonism & related disorders.

[49]  E. Hirsch,et al.  The Role of Glial Reaction and Inflammation in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[50]  C. Rowe,et al.  Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.